276 related articles for article (PubMed ID: 18248639)
1. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.
Chanson P; Borson-Chazot F; Kuhn JM; Blumberg J; Maisonobe P; Delemer B;
Clin Endocrinol (Oxf); 2008 Aug; 69(2):299-305. PubMed ID: 18248639
[TBL] [Abstract][Full Text] [Related]
2. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.
Alexopoulou O; Abrams P; Verhelst J; Poppe K; Velkeniers B; Abs R; Maiter D
Eur J Endocrinol; 2004 Sep; 151(3):317-24. PubMed ID: 15362960
[TBL] [Abstract][Full Text] [Related]
4. ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly.
Álvarez-Escolá C; Venegas-Moreno EM; García-Arnés JA; Blanco-Carrera C; Marazuela-Azpiroz M; Gálvez-Moreno MÁ; Menéndez-Torre E; Aller-Pardo J; Salinas-Vert I; Resmini E; Torres-Vela EM; Gonzalo-Redondo MÁ; Vílchez-Joya R; de Miguel-Novoa MP; Halperín-Rabinovich I; Páramo-Fernández C; de la Cruz-Sugranyes G; Houchard A; Picó-Alfonso AM;
Endocrinol Diabetes Nutr (Engl Ed); 2019 May; 66(5):320-329. PubMed ID: 30773338
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly.
Caron P; Cogne M; Raingeard I; Bex-Bachellerie V; Kuhn JM
Clin Endocrinol (Oxf); 2006 Feb; 64(2):209-14. PubMed ID: 16430722
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
[TBL] [Abstract][Full Text] [Related]
7. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension.
Melmed S; Cook D; Schopohl J; Goth MI; Lam KS; Marek J
Pituitary; 2010; 13(1):18-28. PubMed ID: 19639415
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
Lucas T; Astorga R;
Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly.
Lombardi G; Minuto F; Tamburrano G; Ambrosio MR; Arnaldi G; Arosio M; Chiarini V; Cozzi R; Grottoli S; Mantero F; Bogazzi F; Terzolo M; Tita P; Boscani PF; Colao A
J Endocrinol Invest; 2009 Mar; 32(3):202-9. PubMed ID: 19542735
[TBL] [Abstract][Full Text] [Related]
10. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).
Gutt B; Bidlingmaier M; Kretschmar K; Dieterle C; Steffin B; Schopohl J
Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):139-44. PubMed ID: 15789272
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR.
Ashwell SG; Bevan JS; Edwards OM; Harris MM; Holmes C; Middleton MA; James RA
Eur J Endocrinol; 2004 Apr; 150(4):473-80. PubMed ID: 15080776
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
An Z; Lei T; Duan L; Hu P; Gou Z; Zhang L; Durand-Gasselin L; Wang N; Wang Y; Gu F;
BMC Endocr Disord; 2020 May; 20(1):57. PubMed ID: 32366244
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.
Chanson P; Leselbaum A; Blumberg J; Schaison G
Pituitary; 2000 May; 2(4):269-76. PubMed ID: 11081148
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M;
Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
[TBL] [Abstract][Full Text] [Related]
15. Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study.
Neggers SJ; Pronin V; Balcere I; Lee MK; Rozhinskaya L; Bronstein MD; Gadelha MR; Maisonobe P; Sert C; van der Lely AJ;
Eur J Endocrinol; 2015 Sep; 173(3):313-23. PubMed ID: 26047625
[TBL] [Abstract][Full Text] [Related]
16. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
Cozzi R; Dallabonzana D; Attanasio R; Barausse M; Oppizzi G
Eur J Endocrinol; 1999 Sep; 141(3):267-71. PubMed ID: 10474124
[TBL] [Abstract][Full Text] [Related]
17. Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium.
Ciccarelli A; Daly A; Beckers A
Treat Endocrinol; 2004; 3(2):77-81. PubMed ID: 15743103
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.
Salvatori R; Nachtigall LB; Cook DM; Bonert V; Molitch ME; Blethen S; Chang S;
Pituitary; 2010 Jun; 13(2):115-22. PubMed ID: 19898989
[TBL] [Abstract][Full Text] [Related]
19. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study.
Giustina A; Mazziotti G; Cannavò S; Castello R; Arnaldi G; Bugari G; Cozzi R; Ferone D; Formenti AM; Gatti E; Grottoli S; Maffei P; Maffezzoni F; Montini M; Terzolo M; Ghigo E
J Clin Endocrinol Metab; 2017 Jul; 102(7):2454-2464. PubMed ID: 28419317
[TBL] [Abstract][Full Text] [Related]
20. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study.
Attanasio R; Lanzi R; Losa M; Valentini F; Grimaldi F; De Menis E; Davì MV; Battista C; Castello R; Cremonini N; Razzore P; Rosato F; Montini M; Cozzi R
Endocr Pract; 2008 Oct; 14(7):846-55. PubMed ID: 18996812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
